Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results - Nature Medicine

  • 📰 NatureMedicine
  • ⏱ Reading Time:
  • 26 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 14%
  • Publisher: 53%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

The oral ATR kinase inhibitor camonsertib is well tolerated in patients with DNA damage response-deficient SolidTumors and displays encouraging anti-tumor activity, with the highest response rate in patients with OvarianCancer.

T.A.Y.

has received grants or contracts paid to their institution from Merck, AstraZeneca, Regeneron, Roche, Repare Therapeutics, GlaxoSmithKline and Seagen; consulting fees from Novocure, Merck, AstraZeneca, GlaxoSmithKline, Eisai and Shattuck Labs; payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing or educational events from AstraZeneca, GlaxoSmithKline and Eisai/Merck; and participation on a data safety monitoring board or advisory board from AstraZeneca. N.B.M.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 451. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Stanford Medicine Reveals: Tiny DNA Circles Defying Genetic Laws Drive Cancer FormationTiny circles of DNA harbor cancer-associated oncogenes and immunomodulatory genes promoting cancer development. They arise during the transformation from pre-cancer to cancer, say Stanford Medicine-led team. Tiny circles of DNA that defy the accepted laws of genetics are key drivers of cancer for
Source: SciTechDaily1 - 🏆 84. / 68 Read more »

Inside the nascent industry of AI-designed drugs - Nature MedicineArtificial intelligence tools are beginning to upend the drug discovery pipeline, with several new compounds entering clinical trials.
Source: NatureMedicine - 🏆 451. / 53 Read more »

Researchers and regulators plan for a future without lab animals - Nature MedicineThe US Food and Drug Administration has reduced requirements for preclinical animal testing, leading to a surge of interest in organoids, tissue chips and in silico testing.
Source: NatureMedicine - 🏆 451. / 53 Read more »

Research software engineering accelerates the translation of biomedical research for health - Nature MedicineResearch software engineering accelerates the translation of biomedical research for health. Comment from Dave_Horsfall Muzz_Haniffa and colleagues sangerinstitute
Source: NatureMedicine - 🏆 451. / 53 Read more »

‘MacGyver med’ and rock-and-roll: Event medicine is the ticket for someLarge-event medical services started becoming more formalized about 20 years ago. From Coachella to the Preakness to Lollapalooza, these doctors see it all: blue patients, drunken falls and overheated dancers.
Source: washingtonpost - 🏆 95. / 72 Read more »